Status:
ACTIVE_NOT_RECRUITING
Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma
Lead Sponsor:
Fox Chase Cancer Center
Conditions:
Soft Tissue Sarcoma
Eligibility:
All Genders
18+ years
Brief Summary
The primary aim of this study is to determine the utility of TOPO2A as a biomarker for sensitivity to doxorubicin or its derivatives. Patients whose planned therapy is doxorucibin or doxil single agen...
Eligibility Criteria
Inclusion
- Patients must consent to providing tumor tissue prior to initiation of therapy if sufficient archival tissue is not available. Archival tissue is permitted if no other anticancer treatment was given after the tissue was obtained (not including surgery or radiation). If a biopsy is required, the treating physician should ensure that this can be done safely.
- Patients with STS will be eligible for the trial if their next planned chemotherapy will include single agent doxorubicin or doxil. Patients who will be receiving concomitant therapy with olaratumab will be allowed to participate.
- Sarcoma subtypes of angiosarcoma, epithelioid sarcoma, leiomyosarcoma, fibrosarcoma, myxofibrosarcoma, synovial sarcoma, pleomorphic rhabdomyosarcoma, undifferentiated pleomorphic sarcoma, liposarcoma (excluding well-differentiated) and malignant peripheral nerve sheath tumor will be included. These are subtypes for which a targeted therapy is not standard of care. All other subtypes will be included on a case by case basis as determined by the principle investigator.
- ≥ 18 years of age.
- Ability to understand and willingness to sign a written informed consent and HIPPA document
- Measurable disease by RECIST 1.1 criteria (at least one target lesion outside of previous radiation fields or progressed within a previous radiation field).
- Life expectancy of at least 3 months.
- All women of childbearing potential must have a negative serum pregnancy test and all subjects must agree to use effective means of contraception (surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 6 months after the last dose. Post-menopausal women must meet the criteria of 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels \>35 mIU/ml (IU/L).
- Patients must have normal organ and marrow function as defined below
- Absolute neutrophil count \> 1,500/mcL
- Platelets \> 100,000/mcL
- Total bilirubin ≤ 1.5 X upper limit of normal (ULN)
- AST/ALT (SGOT/SGPT) ≤ 3 X institutional normal limits; if liver metastases are present then ≤ 5 X ULN are allowed
Exclusion
- Patients may not be receiving any other investigational agents, chemotherapy, radiation therapy or hormonal therapy (i.e. aromatase inhibitors for leiomyosarcoma), with the exception of olaratumab
- Pregnant or breast feeding women.
- Any concomitant medical issue that in the opinion of the treating physician would confound survival from sarcoma (e.g. other active cancer, symptomatic brain metastases, cardiac conditions).
Key Trial Info
Start Date :
August 12 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2027
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04055753
Start Date
August 12 2016
End Date
October 1 2027
Last Update
December 4 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111